BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2 (LGMD2i) with new subsidiary ML Bio Solutions

September 5, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search